Curis Inc (CRIS)
Curis Inc. is a Nasdaq-listed biotechnology company focused on discovering and developing drug candidates for the treatment of human cancers in the United States. Its clinical-stage pipeline includes emavusertib, an oral small-molecule IRAK4 kinase inhibitor being evaluated in a Phase 1/2 expansion study in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. The company also develops fimepinostat for relapsed or refractory diffuse large B-cell lymphoma, along with CA-170 and CA-327, both oral small-molecule programs targeting immune-oncology pathways. Curis has collaboration agreements with Genentech and Roche related to Erivedge, as well as with Aurigene Discovery Technologies for small-molecule programs in immuno-oncology and precision oncology. Founded in 2000, the company is headquartered in Lexington, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRIS
|
$1.60
|
59.9% Upside
|
Bargain
|
$42.67 4,166.7% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 11, 2026
|
0.5x
|
0.5x
|
2.132 M
|
-1.795 M
|
31.4%
|
87.9%
|
-443.0
|
144.6%
|
